Olaratumab, sold under the brand name Lartruvo, is a monoclonal antibody medication developed by Eli Lilly and Company for the treatment of solid tumors...
11 KB (951 words) - 07:29, 1 July 2024
Radotinib Quizartinib Ripretinib Sunitinib Sorafenib Toceranib Antibodies: Olaratumab Ramucirumab Tovetumab RET (GFL) SCF (c-Kit) Agonists: Ancestim Stem cell...
121 KB (13,799 words) - 18:32, 22 August 2024
Radotinib Quizartinib Ripretinib Sunitinib Sorafenib Toceranib Antibodies: Olaratumab Ramucirumab Tovetumab RET (GFL) SCF (c-Kit) Agonists: Ancestim Stem cell...
68 KB (5,999 words) - 20:41, 31 August 2024
Radotinib Quizartinib Ripretinib Sunitinib Sorafenib Toceranib Antibodies: Olaratumab Ramucirumab Tovetumab RET (GFL) SCF (c-Kit) Agonists: Ancestim Stem cell...
149 KB (15,717 words) - 06:34, 13 August 2024
Radotinib Quizartinib Ripretinib Sunitinib Sorafenib Toceranib Antibodies: Olaratumab Ramucirumab Tovetumab RET (GFL) SCF (c-Kit) Agonists: Ancestim Stem cell...
92 KB (8,671 words) - 18:15, 17 August 2024
to be a human polyclonal antibody (-pab) acting on the immune system. Olaratumab is an antineoplastic. Its name is composed of the components olara-t-u-mab...
38 KB (3,088 words) - 05:02, 8 August 2024
Radotinib Quizartinib Ripretinib Sunitinib Sorafenib Toceranib Antibodies: Olaratumab Ramucirumab Tovetumab RET (GFL) SCF (c-Kit) Agonists: Ancestim Stem cell...
31 KB (3,430 words) - 05:24, 28 August 2024
Radotinib Quizartinib Ripretinib Sunitinib Sorafenib Toceranib Antibodies: Olaratumab Ramucirumab Tovetumab RET (GFL) SCF (c-Kit) Agonists: Ancestim Stem cell...
13 KB (1,177 words) - 02:19, 4 September 2024
soravtansine Mogamulizumab Moxetumomab pasudotox Naxitamab Necitumumab Nivolumab Olaratumab Oportuzumab monatox Pembrolizumab Polatuzumab vedotin Prolgolimab Ramucirumab...
12 KB (794 words) - 03:30, 2 September 2024
Kesimpta mab human CD20 Y chronic lymphocytic leukemia, multiple sclerosis Olaratumab Lartruvo mab human PDGFRA Y cancer Oleclumab mab human 5'-nucleotidase...
136 KB (4,020 words) - 07:14, 15 August 2024